Glucagon-like peptide-1 (GLP-1) medications like semaglutide ( Wegovy , Ozempic ) and tirzepatide ( Zepbound , Mounjaro ) have gained traction over the last few years
Side Effects and Safety Considerations Both peptides have relatively favorable safety profiles based on existing research and clinical use in Russia over several decades
We concentrate on: Optimization of hormones like insulin, cortisol, estrogen, and testosterone Customized metabolic evaluations Long-term fat reduction techniques Performance and long-term health This guarantees that your outcomes are balanced, safe, and sustainable in addition to being quick
These compounds, including GLP-1, GIP, DPP-4, and PYY, are crucial in how our bodies regulate appetite, blood sugar, and fat storage
This approach ensures that late entrants (eg, those entering in January 2025) contribute data only for the duration of their observed follow-up and are appropriately censored before reaching the 1-, 3-, or 5-year marks if their record does not extend that far
The immense telehealth and compounding boom of these medications due to shortage led to an unpredictable, and at times less than safe, environment for providers and patients alike
